Europe Radiotherapy Market Overview
Markets such as Europe are ripening with both old and new technologies. The most often arising forms of the disease in the European region are colorectal, breast, prostate, and lung cancers.
Radiotherapy is a painless treatment and is extensively used in cancer treatment. Radiotherapy is centered on the principle of damage of cancerous cells by destructing their DNA inside these cells by radiations. It slows down the growth of cancerous cells and is intended at providing comforting care to relieve the patient of symptoms.
The Europe Radiotherapy Market is driven by numeral factors like the surge in the number of cancer patients, decrease in the cost of treatment in several developed areas, enormous government and non-government funds in Research and Development of cancer treatment and inclination for non-invasive techniques of treatment. In radiotherapy, harm to neighboring healthy cells by the high dosage of radiation is a side-effect which could pose a risk for market growth. The several side-effects of radiation treatment such as fatigue, skin problems, nausea, fertility issues, hair loss, appetite loss, diarrhea could possibly obstruct radiotherapy devices market growth.
Europe Radiotherapy Market Forecast Report (2018-2023)
Europe Radiotherapy Market was worth $1.53 Billion in 2018 and estimated to be growing at a CAGR of 5.71%, to reach $2.02 billion by 2023.
Europe Radiotherapy Market Segmentation
The Europe radiotherapy market is segmented on the basis of type into External beam radiation therapy, internal beam radiation therapy, and systemic radiation therapy. External beam radiation therapy is sub-segmented into Intensity-modulated radiation therapy (IMRT), Image-guided radiation therapy (IGRT), Tomotherapy, Stereotactic radiosurgery, Stereotactic body radiation therapy, and Proton therapy. Based on the application the market is segregated into Skin & Lip Cancer, Head & Neck Cancer, Breast Cancer, Prostate Cancer, Cervical Cancer, Lung Cancer, and Spine Cancer. On the basis of equipment type market is bifurcated into Linear accelerators, Radiation therapy simulators and Treatment planning systems. The prostate cancer application segment is estimated to hold the largest share in both external beam radiotherapy market along with internal radiotherapy market.
Based on geography the market is analyzed under various regions namely, Germany, France, Italy, Spain, and U.K. France is expected to grow at highest CAGR among the countries in European region during the forecast period from 2018-2023.
Key Developments in the Market
Major Players:
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 External Beam Radiation Therapy
5.1.1.1 Intensity-Modulated Radiation Therapy (IMRT)
5.1.1.2 Image-Guided Radiation Therapy (IGRT)
5.1.1.3 Tomotherapy
5.1.1.4 Stereotactic Radiosurgery
5.1.1.5 Stereotactic body Radiation Therapy
5.1.1.6 Proton Therapy
5.1.2 Internal Beam Radiation Therapy
5.1.3 Systemic Radiation Therapy
5.2 By Application
5.2.1 Skin & Lip Cancer
5.2.2 Head & Neck Cancer
5.2.3 Breast Cancer
5.2.4 Prostate Cancer
5.2.5 Cervical Cancer
5.2.6 Lung Cancer
5.2.7 Spine Cancer
5.3 By Equipment Type
5.3.1 Linear Accelerators
5.3.2 Radiation Therapy Simulators
5.3.3 Treatment Planning Systems
6. Geographical Analysis
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.
8. Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9. Market Leaders' Analysis
9.1 Nordion Inc.
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Strategic Evaluation and Operations
9.1.4 Financial analysis
9.1.5 Legal issues
9.1.6 Recent Developments
9.1.7 SWOT analysis
9.1.8 Analyst View
9.2 RaySearch Laboratories AB
9.3 Ion Beam Applications SA
9.4 C. R. Bard Inc.
9.5 Mevion Medical Systems Inc.
9.6 Varian Medical Systems Inc.
9.7 IsoRay Medical Inc.
9.8 Elekta AB
9.9 Accuray Incorporated
9.10 Mitsubishi Electric Corporation
10. Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations, and Joint Ventures
10.4 New Product Launches
11. Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
